TriSalus Life Sciences (NASDAQ:TLSIW) Shares Up 24% – Here’s Why

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW)’s stock price shot up 24% during trading on Monday . The stock traded as high as $1.85 and last traded at $1.60. 10,043 shares changed hands during mid-day trading, an increase of 3% from the average session volume of 9,749 shares. The stock had previously closed at $1.29.

TriSalus Life Sciences Stock Up 24.0%

The company has a 50-day moving average price of $1.41 and a two-hundred day moving average price of $1.52.

Institutional Trading of TriSalus Life Sciences

An institutional investor recently raised its position in TriSalus Life Sciences stock. Citadel Advisors LLC lifted its position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) by 439.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 126,876 shares of the company’s stock after purchasing an additional 103,336 shares during the period. Citadel Advisors LLC’s holdings in TriSalus Life Sciences were worth $199,000 as of its most recent SEC filing.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage medical device company focused on developing minimally invasive technologies to enhance the precision and efficacy of cancer radiation therapy. The company’s lead product, the TriMark™ Tissue Marker System, is designed to provide high-visibility soft-tissue fiducial markers that assist oncologists in accurately targeting tumors during radiotherapy. By deploying bio-absorbable markers directly into tumor beds, TriSalus aims to improve treatment planning, patient comfort and long-term follow-up imaging.

Founded in 2015 and headquartered in Plymouth, Minnesota, TriSalus Life Sciences pursues a platform approach to oncology treatment, with research and development efforts centered on novel delivery devices and advanced imaging solutions.